tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DSGN Stock Latest News

Design Therapeutics Reports Q3 2025 Financial Results
Company AnnouncementsDesign Therapeutics Reports Q3 2025 Financial Results
2d ago
DSGN
Design Therapeutics reports Q3 EPS (30c), consensus (34c)
PremiumThe Fly
Design Therapeutics reports Q3 EPS (30c), consensus (34c)
3d ago
DSGN
Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy
PremiumCompany Announcements
Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy
12d ago
DSGN
Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia
PremiumCompany Announcements
Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia
12d ago
DSGN
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia
PremiumCompany Announcements
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia
12d ago
DSGN
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe FlyCitizens JMP healthcare analysts hold an analyst/industry conference call
1M ago
BIIB
DSGN
Design Therapeutics Appoints Justin Gover as Director
Premium
Company Announcements
Design Therapeutics Appoints Justin Gover as Director
2M ago
8K
DSGN
Cohen’s Point72 reports 5.2% passive stake in Design Therapeutics
Premium
The Fly
Cohen’s Point72 reports 5.2% passive stake in Design Therapeutics
2M ago
DSGN
Design Therapeutics Reports Increased R&D Expenses Amid Net Loss
PremiumCompany Announcements
Design Therapeutics Reports Increased R&D Expenses Amid Net Loss
3M ago
DSGN
Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial Caution
PremiumRatings
Design Therapeutics: Hold Rating Amid Regulatory Hurdles and Financial Caution
3M ago
DSGN
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold
PremiumCompany Announcements
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold
3M ago
8K
DSGN
Design Therapeutics reports Q2 EPS (34c), consensus (33c)
PremiumThe Fly
Design Therapeutics reports Q2 EPS (34c), consensus (33c)
3M ago
DSGN
Design Therapeutics Faces Financial Strain Amid International Trade Challenges
PremiumCompany AnnouncementsDesign Therapeutics Faces Financial Strain Amid International Trade Challenges
4M ago
DSGN
Design Therapeutics Confirms Directors at Annual Meeting
Premium
Company Announcements
Design Therapeutics Confirms Directors at Annual Meeting
5M ago
8K
DSGN
Design Therapeutics announces first FA patient dosed in RESTORE-FA trial
Premium
The Fly
Design Therapeutics announces first FA patient dosed in RESTORE-FA trial
5M ago
DSGN
Design Therapeutics files $300M mixeds securities shelf
PremiumThe Fly
Design Therapeutics files $300M mixeds securities shelf
6M ago
DSGN
Controversial doctor Vinay Prasad named CBER director, STAT reports
PremiumThe Fly
Controversial doctor Vinay Prasad named CBER director, STAT reports
6M ago
DYN
RNA
Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
PremiumRatings
Cautious Optimism for Design Therapeutics: Hold Rating Amid Promising Phase 1 Results and Extended Development Timeline
6M ago
DSGN
Design Therapeutics announces data from Phase 1 SAD/MAD trial of DT-168
PremiumThe Fly
Design Therapeutics announces data from Phase 1 SAD/MAD trial of DT-168
6M ago
DSGN
RBC sees Makary interview as potentially positive for biotech stocks
PremiumThe FlyRBC sees Makary interview as potentially positive for biotech stocks
7M ago
DYN
RNA
Design Therapeutics appoints Chris Storgard as CMO
Premium
The Fly
Design Therapeutics appoints Chris Storgard as CMO
7M ago
DSGN
Design Therapeutics price target raised to $5 from $4 at RBC Capital
Premium
The Fly
Design Therapeutics price target raised to $5 from $4 at RBC Capital
8M ago
DSGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >